Tom Daniel, M.D.

Tom is currently venture partner at ARCH Venture Partners, chairman at Vividion Therapeutics and a director at Sana Biotechnology, VIR Biotechnology, Magenta Therapeutics, ImmunsanT, Zafgen and Gossamer Bio. He also serves as trustee for Reed College, on the board of the Lupus Research Alliance and as chairman of the Oversight Committee of The Scripps Research Institute. Previously, Tom was president, global research and early development at Celgene Corporation  as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and advanced and commercialized innovative medicines in oncology and inflammatory diseases. He previously served as chief scientific officer and director of Ambrx, as vice president of research at Amgen, and as senior vice president of discovery research at Immunex Corporation.

Tom was formerly Hakim Professor of Medicine at Vanderbilt University Medical Center.  He earned his medical degree and trained in nephrology and molecular genetics at the University of Texas, Southwestern, and completed a medical residency at Massachusetts General Hospital.